Jazz Pharmaceuticals plc Files 2023 Annual Report on Form 10-K

TL;DR

<b>Jazz Pharmaceuticals plc has filed its annual 10-K report for the fiscal year ending December 31, 2023.</b>

AI Summary

Jazz Pharmaceuticals plc (JAZZ) filed a Annual Report (10-K) with the SEC on February 28, 2024. Jazz Pharmaceuticals plc filed its 2023 Form 10-K on February 28, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal business is in Pharmaceutical Preparations (SIC 2834). Jazz Pharmaceuticals plc is incorporated in L2. The company's principal executive offices are located in Dublin, Ireland.

Why It Matters

For investors and stakeholders tracking Jazz Pharmaceuticals plc, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Jazz Pharmaceuticals' financial performance, business operations, and risk factors for the fiscal year 2023, which is crucial for investors to assess the company's health and future prospects. The detailed financial data and disclosures within the 10-K allow stakeholders to understand revenue streams, profitability, debt levels, and other key financial metrics, enabling informed investment decisions.

Risk Assessment

Risk Level: medium — Jazz Pharmaceuticals plc shows moderate risk based on this filing. The company operates in the highly regulated pharmaceutical industry, facing risks related to drug development, clinical trials, regulatory approvals, and market competition, as detailed in its risk factors.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Jazz Pharmaceuticals' performance and potential challenges in the pharmaceutical market.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed Period of Report)
• 2024-02-28 — Filing Date (As of Date)
• 142 — Public Document Count (Document Count)

Key Players & Entities

• Jazz Pharmaceuticals plc (company) — Filer
• 2023 (date) — Fiscal Year End
• 2024-02-28 (date) — Filing Date
• 2834 (dollar_amount) — Standard Industrial Classification
• L2 (company) — State of Incorporation
• Dublin (company) — Business Address City

FAQ

Industry Context

Jazz Pharmaceuticals plc operates within the pharmaceutical industry, focusing on the development and commercialization of therapies for significant unmet medical needs.

Regulatory Implications

The pharmaceutical industry is subject to extensive regulation by bodies like the FDA and EMA, impacting drug approval processes, manufacturing standards, and marketing practices.

What Investors Should Do

1. Review the full 10-K filing for detailed financial statements and management discussion.
2. Analyze the risk factors section to understand potential challenges and uncertainties.
3. Compare the 2023 results with previous years to identify trends and performance changes.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
• 2024-02-28: Filing Date — Date the 10-K was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial filing data extracted; comparison with prior filings requires access to those documents.

Key Financial Figures

• $0.0001 — istered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Market
• $1,273.0 m — n 2023, net product sales of Xywav were $1,273.0 million, which represented 34% of our tot
• $569.7 m — n 2023, net product sales of Xyrem were $569.7 million, which represented 15% of our tot

Filing Documents

• jazz-20231231.htm (10-K) — 3105KB
• jazzq42023ex46.htm (EX-4.6) — 102KB
• jazzq42023ex1017a.htm (EX-10.17A) — 144KB
• jazzq42023ex1017b.htm (EX-10.17B) — 8KB
• jazzq42023ex1018i.htm (EX-10.18I) — 216KB
• jazzq42023ex1020a.htm (EX-10.20A) — 275KB
• jazzq42023ex1021c.htm (EX-10.21C) — 121KB
• jazzq42023ex211.htm (EX-21.1) — 9KB
• jazzq42023ex231.htm (EX-23.1) — 3KB
• jazzq42023ex311.htm (EX-31.1) — 10KB
• jazzq42023ex312.htm (EX-31.2) — 10KB
• jazzq42023ex321.htm (EX-32.1) — 7KB
• jazzq42023ex971.htm (EX-97.1) — 45KB
• jazz-20231231_g1.jpg (GRAPHIC) — 44KB
• jazz-20231231_g2.jpg (GRAPHIC) — 43KB
• 0001232524-24-000015.txt (&nbsp;) — 16738KB
• jazz-20231231.xsd (EX-101.SCH) — 97KB
• jazz-20231231_cal.xml (EX-101.CAL) — 169KB
• jazz-20231231_def.xml (EX-101.DEF) — 563KB
• jazz-20231231_lab.xml (EX-101.LAB) — 1335KB
• jazz-20231231_pre.xml (EX-101.PRE) — 909KB
• jazz-20231231_htm.xml (XML) — 2338KB

Risk Factors

Item 1A. Risk Factors 35

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 65

Cybersecurity

Item 1C. Cybersecurity 65

Properties

Item 2. Properties 67

Legal Proceedings

Item 3. Legal Proceedings 67

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 67 PART II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 68

Reserved

Item 6. Reserved 71

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 72

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 96

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 98

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 98

Controls and Procedures

Item 9A. Controls and Procedures 98

Other Information

Item 9B. Other Information 100

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 100 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 100

Executive Compensation

Item 11. Executive Compensation 100

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 101

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 101

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 101 PART IV

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 101

Form 10-K Summary

Item 16. Form 10-K Summary 108

Signatures

Signatures 109 We own or have rights to various copyrights, trademarks, and trade names used in our business in the U.S. and/or other countries, including the following: Jazz Pharmaceuticals , Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Epidyolex (the trade name in Europe and other countries outside the U.S. for Epidiolex), Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Enrylaze (the trade name in Europe and other countries outside the U.S. and Canada for Rylaze), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium), Defitelio (defibrotide), Vyxeos (daunorubicin and cytarabine) liposome for injection, Vyxeos liposomal 44 mg/100 mg powder for concentrate for solution for infusion, CombiPlex and Sativex (nabiximols) oral solution. This Annual Report on Form 10K also includes trademarks, service marks and trade names of other companies. Trademarks, service marks and trade names appearing in this Annual Report on Form 10K are the property of their respective owners. 2 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expect," "plan," "anticipate," "believe," "estimate," "project," "predict," "propose," "intend," "continue," "potential," "possible," "strive," "seek," "designed," "goal", "foreseeable," "likely," "unforeseen" and similar expressions intended to identify forward-looking statem

Business

Item 1. Business Overview Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases - often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Our strategy for growth is rooted in executing commercial launches and ongoing commercialization initiatives; advancing robust research and development, or R&D, programs and delivering impactful clinical results; effectively deploying capital to strengthen the prospects of achieving our short- and long-term goals through strategic corporate development; and delivering strong financial performance. We focus on patient populations with high unmet needs. We identify and develop differentiated therapies for these patients that we expect will be long-lived assets and that we can support with an efficient commercialization model. In addition, we leverage our efficient, scalable operating model and integrated capabilities across our global infrastructure to effectively reach patients around the world. In January 2022, we announced our Vision 2025, which aims to deliver sustainable growth and enhanced value, driving our continued transformation to an innovative, high-growth global pharmaceutical leader. The three core components of our Vision 2025 focus on commercial execution, pipeline productivity and operational excellence. Our lead marketed products, listed below, are approved in countries around the world to improve patient care. Neuroscience Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution , a

View Full Filing

View this 10-K filing on SEC EDGAR